You are here: Industry Insights > PSA

News List

VA Study Shows Black Men Twice as Likely to Develop Prostate Cancer as Whites drugs.com
January 19, 2022
Even in a setting where white and Black people have equal access to medical care...
FDA approves Novartis’ Cosentyx to treat arthritis in children and adolescents Pharmaceutical-Business-Review
December 27, 2021
A fully human biologic, Cosentyx is developed to directly target interleukin-17A (IL-17A), a cytokine.
Serum Biomarkers Can Differentiate Psoriatic Arthritis, RA drugs.com
December 21, 2021
A serum protein biomarker panel can differentiate patients with early inflammatory arthritis with psoriatic arthritis (PsA) from those with rheumatoid arthritis (RA), according to a study recently published in Arthritis & Rheumatology.
Statin Use Does Not Change Benefits of Prostate Cancer Screening Drugs
December 09, 2021
Prostate-specific antigen (PSA) screening is associated with a lower incidence of advanced prostate cancer regardless of statin use, according to a study published online Nov. 24 in JAMA Oncology.
Tremfya? shows promise in Phase III psoriatic arthritis study EuropeanPharmaceuticalReview
November 03, 2021
Janssen has announced six new analyses of Phase III data from the DISCOVER-1 and DISCOVER-2 clinical trials?, which demonstrate Tremfya? (guselkumab) inhibited radiographic progression versus placebo...
Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2506 americanpharmaceuticalreview
June 10, 2021
Bio-Thera Solutions Ltd., a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase III clinical study for BAT2506, a proposed biosimilar of Simponi? (golimumab).
Tremfya? improves psoriatic arthritis joint function and skin clearance europeanpharmaceuticalreview
June 08, 2021
Over 50 percent of psoriatic arthritis patients treated with Tremfya? (guselkumab) achieved ≥20 percent improvement in joint symptoms and complete skin clearance at one year.
J&J’s Tremfya shows significant improvements for post-TNFi psoriatic arthritis patients pharmatimes
June 04, 2021
Johnson & Johnson’s (J&J) interleukin-23 (IL-23) Tremfya has demonstrated positive results in post-tumour necrosis factor (TNF) inhibitor-treated psoriatic arthritis (PsA) patients.
NICE green lights Tremfya to treat active psoriatic arthritis pharmatimes
June 01, 2021
Janssen’s IL-23 inhibitor Tremfya has been accepted for NHS use by the UK’s National Institute for Health and Care Excellence (NICE) for the treatment of active psoriatic arthritis (PsA).
Data shows long-term efficacy of Tremfya? in active psoriatic arthritis europeanpharmaceuticalreview
March 18, 2021
The joint and skin response rates of adults with active psoriatic arthritis observed with Tremfya? (guselkumab) were maintained over two years.